Cutler Group LP Altimmune, Inc. Put Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 Apr 19, 2024	SELL	$8.22 - $13.81 $9,042 - $15,191	-1,100 Reduced 84.62%	200 $0
Q4 2023 Jan 18, 2024	BUY	$2.14 - $11.62 $2,782 - $15,105	1,300 New	1,300 $0
Q2 2023 Jul 18, 2023	SELL	$3.45 - $5.97 $59,685 - $103,281	-17,300 Reduced 97.19%	500 $4,000
Q1 2023 May 01, 2023	BUY	$4.19 - $16.83 $51,118 - $205,325	12,200 Added 217.86%	17,800 $31,000
Q4 2022 Feb 07, 2023	BUY	$8.74 - $16.45 $4,370 - $8,225	500 Added 9.8%	5,600 $1,000
Q3 2022 Oct 25, 2022	BUY	$10.67 - $22.41 $54,417 - $114,291	5,100 New	5,100 $11,000
Q3 2021 Oct 26, 2021	BUY	$8.43 - $16.81 $41,307 - $82,369	4,900 Added 39.84%	17,200 $2,000
Q2 2021 Jul 19, 2021	BUY	$9.85 - $16.46 $99,485 - $166,246	10,100 Added 459.09%	12,300 $10,000
Q3 2020 Oct 27, 2020	SELL	$9.93 - $33.26 $21,846 - $73,172	-2,200 Reduced 50.0%	2,200 $2,000
Q2 2020 Jul 22, 2020	BUY	$2.9 - $10.71 $12,760 - $47,124	4,400 New	4,400 $3,000

189

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $343M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.